Cullinan Therapeutics (CGEM) Share-based Compensation: 2020-2024
Historic Share-based Compensation for Cullinan Therapeutics (CGEM) over the last 5 years, with Dec 2024 value amounting to $37.8 million.
- Cullinan Therapeutics' Share-based Compensation rose 0.08% to $7.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $30.4 million, marking a year-over-year increase of 8.87%. This contributed to the annual value of $37.8 million for FY2024, which is 24.27% up from last year.
- Latest data reveals that Cullinan Therapeutics reported Share-based Compensation of $37.8 million as of FY2024, which was up 24.27% from $30.4 million recorded in FY2023.
- In the past 5 years, Cullinan Therapeutics' Share-based Compensation registered a high of $37.8 million during FY2024, and its lowest value of $14.9 million during FY2020.
- For the 3-year period, Cullinan Therapeutics' Share-based Compensation averaged around $32.1 million, with its median value being $30.4 million (2023).
- Data for Cullinan Therapeutics' Share-based Compensation shows a peak YoY spiked of 63.48% (in 2021) over the last 5 years.
- Yearly analysis of 5 years shows Cullinan Therapeutics' Share-based Compensation stood at $14.9 million in 2020, then surged by 63.48% to $24.4 million in 2021, then climbed by 14.70% to $28.0 million in 2022, then rose by 8.87% to $30.4 million in 2023, then rose by 24.27% to $37.8 million in 2024.